Doxorubicin (DOX) is a chemotherapeutic drug that is utilized for solid tumors and
hematologic malignancies, but its clinical application is hampered by life-threatening …

Doxorubicin (DOX) is the most widely used anthracycline anticancer agent; however, its
cardiotoxicity limits its clinical efficacy. Numerous studies have elucidated the mechanisms …

The cardiovascular system requires iron to maintain its high energy demands and metabolic
activity. Iron plays a critical role in oxygen transport and storage, mitochondrial function, and …

Background Doxorubicin (DOX) is a powerful anti-tumor anthracycline drug. However, its
clinical use is limited due to the side effect of cardiotoxicity. Tanshinone I (Tan I) is one of the …

Abstract Doxorubicin (DOX)‐induced cardiotoxicity (DoIC) is a major side effect for cancer
patients. Recently, ferroptosis, triggered by iron overload, is demonstrated to play a role in …

Background Doxorubicin (DOX)-induced cardiotoxicity (DIC) is a major impediment to its
clinical application. It is indispensable to explore alternative treatment molecules or drugs for …

Doxorubicin (DOX)-related cardiotoxicity has been recognized as a serious complication of
cancer chemotherapy. Effective targeted strategies for myocardial protection in addition to …

Background: Several cardiovascular risk factors have been suggested to be associated with
anthracycline-induced cardiotoxicity, but their quantitative effects have not reached a …

Tumour metastasis is one of the major factors leading to poor prognosis as well as lower
survival among cancer patients. A number of studies investigating the inhibition of tumour …

Lung cancer is the most common malignancy in the world, with a high mortality rate.
Nevertheless, therapies to act effectively against lung cancer remain elusive. So far …